Author:
O'Callaghan C H,Acred P,Harper P B,Ryan D M,Kirby S M,Harding S M
Abstract
GR 20263 is a new broad-spectrum injectable cephalosporin which is stable to most beta-lactamases. Its in vitro activities were of the same order as those of cefotaxime against most gram-negative bacteria, were clearly inferior to cefotaxime against Staphylococcus aureus, but were significantly more active against Pseudomonas aeruginosa. Against the 25 strains used, GR 20263 was significantly more active than any of the other agents tested: piperacillin, azlocillin, gentamicin, amikacin, and carbenicillin. GR 20263 protected mice against experimental infections with P. aeruginosa more effectively than other beta-lactam antibiotics; its general effectiveness in this test was comparable with gentamicin. Studies on human volunteers showed that it produces high, long-lasting blood levels, with much of the antibiotic being recovered in the urine. Intramuscular and intravenous injections were well tolerated by the volunteers, and there were no untoward side effects.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference7 articles.
1. Experimental evaluation of HR 756 a new cephalosporin derivative: pre-clinical study;Heymes R.;Infection,1977
2. The action of cephaloridine and cloxacillin or methicillin against ,6-lactamase-producing gram-negative bacteria;O'Callaghan C. H.;J. Gen. Microbiol.,1967
3. O'Callaghan C. H. P. W. Muggleton and G. W. Ross. 1969. Effects of -lactamase from gram-negative organisms on cephalosporins and penicillins p. 57-63. Antimicrob. Agents Chemother. 1968.
4. Cefuroxime-a new cephalosporin antibiotic;O'Callaghan C. H.;J. Antbiot. Jpn.,1976
5. New cephalosporin derivatives with high antibacterial activities;Ochiai M.;Chem. Phann. Bull.,1977
Cited by
232 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献